• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.

作者信息

Skrtić Marko, Yang Gary K, Perkins Bruce A, Soleymanlou Nima, Lytvyn Yuliya, von Eynatten Maximilian, Woerle Hans J, Johansen Odd Erik, Broedl Uli C, Hach Thomas, Silverman Melvin, Cherney David Z I

机构信息

Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, 585 University Ave, 8N-845, Toronto, ON, Canada, M5G 2N2.

出版信息

Diabetologia. 2014 Dec;57(12):2599-602. doi: 10.1007/s00125-014-3396-4. Epub 2014 Oct 4.

DOI:10.1007/s00125-014-3396-4
PMID:25280671
Abstract
摘要

相似文献

1
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.1型糖尿病合并肾高滤过患者肾小球血流动力学对SGLT2抑制的反应特征
Diabetologia. 2014 Dec;57(12):2599-602. doi: 10.1007/s00125-014-3396-4. Epub 2014 Oct 4.
2
SGLT2 Inhibitors and the Diabetic Kidney.钠-葡萄糖协同转运蛋白 2 抑制剂与糖尿病肾脏疾病
Diabetes Care. 2016 Aug;39 Suppl 2:S165-71. doi: 10.2337/dcS15-3006.
3
Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?钠-葡萄糖协同转运蛋白2（SGLT2）抑制可减轻肾小球高滤过：SGLT2抑制剂在糖尿病肾病中是否发挥作用？
Circulation. 2014 Feb 4;129(5):542-4. doi: 10.1161/CIRCULATIONAHA.113.007071. Epub 2013 Dec 13.
4
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.恩格列净，一种钠-葡萄糖共转运蛋白 2 抑制剂，在 1 型糖尿病治疗中的应用。
Expert Opin Investig Drugs. 2014 Jun;23(6):875-82. doi: 10.1517/13543784.2014.909407. Epub 2014 Apr 19.
5
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.1 型糖尿病患者钠-葡萄糖共转运蛋白 2 抑制剂的肾脏血流动力学效应。
Circulation. 2014 Feb 4;129(5):587-97. doi: 10.1161/CIRCULATIONAHA.113.005081. Epub 2013 Dec 13.
6
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的降压及肾脏作用机制
Hypertension. 2020 Apr;75(4):894-901. doi: 10.1161/HYPERTENSIONAHA.119.11684. Epub 2020 Mar 2.
7
The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.SGLT2 抑制剂在糖尿病中的作用机制及治疗潜力。
Annu Rev Med. 2015;66:255-70. doi: 10.1146/annurev-med-051013-110046. Epub 2014 Oct 17.
8
[Renal SGLT2 inhibitors: a new type of oral anti-hyperglycemia drugs].[肾钠-葡萄糖协同转运蛋白2抑制剂：一类新型口服降糖药]
Sheng Li Ke Xue Jin Zhan. 2010 Dec;41(6):453-6.
9
Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?钠-葡萄糖共转运蛋白-2 抑制剂：除了降低血糖，还有保护肾脏的潜力？
Kidney Int. 2014 Oct;86(4):693-700. doi: 10.1038/ki.2013.451. Epub 2013 Nov 20.
10
Empagliflozin in the treatment of type 2 diabetes: evidence to date.恩格列净治疗2型糖尿病：迄今的证据
Drug Des Devel Ther. 2015 Oct 30;9:5793-803. doi: 10.2147/DDDT.S69926. eCollection 2015.

引用本文的文献

1
Effect of Pharmacogenetics on Renal Outcomes of Heart Failure Patients with Reduced Ejection Fraction (HFrEF) in Response to Dapagliflozin.药物遗传学对射血分数降低的心力衰竭（HFrEF）患者使用达格列净治疗后肾脏结局的影响。
Pharmaceutics. 2025 Jul 24;17(8):959. doi: 10.3390/pharmaceutics17080959.
2
SGLT2 Inhibitors: Multifaceted Therapeutic Agents in Cardiometabolic and Renal Diseases.钠-葡萄糖协同转运蛋白2抑制剂：心血管代谢疾病和肾脏疾病中的多面治疗药物
Metabolites. 2025 Aug 7;15(8):536. doi: 10.3390/metabo15080536.
3
SGLT2-Inhibition in Patients With Alport Syndrome.

本文引用的文献

1
Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.钠-葡萄糖共转运蛋白 2 抑制剂在 1 型糖尿病中的血糖控制作用：一项为期 8 周的开放标签概念验证试验结果。
Diabetes Care. 2014 May;37(5):1480-3. doi: 10.2337/dc13-2338. Epub 2014 Mar 4.
2
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.恩格列净对无并发症的1型糖尿病患者动脉僵硬度和心率变异性的影响。
Cardiovasc Diabetol. 2014 Jan 29;13:28. doi: 10.1186/1475-2840-13-28.
3
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
阿尔波特综合征患者的钠-葡萄糖协同转运蛋白2抑制作用
Kidney Int Rep. 2024 Sep 24;9(12):3490-3500. doi: 10.1016/j.ekir.2024.09.014. eCollection 2024 Dec.
4
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Cardiovascular Outcomes: A Review of Literature.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂与心血管结局：文献综述
Cureus. 2024 Jul 4;16(7):e63796. doi: 10.7759/cureus.63796. eCollection 2024 Jul.
5
Glycolytic lactate in diabetic kidney disease.糖尿病肾病中的糖酵解乳酸。
JCI Insight. 2024 Jun 10;9(11):e168825. doi: 10.1172/jci.insight.168825.
6
Innovative Treatments to Counteract Endothelial Dysfunction in Chronic Kidney Disease Patients.对抗慢性肾脏病患者内皮功能障碍的创新疗法。
Biomedicines. 2024 May 14;12(5):1085. doi: 10.3390/biomedicines12051085.
7
Modern-Day Therapeutics and Ongoing Clinical Trials against Type 2 Diabetes Mellitus: A Narrative Review.现代治疗方法与2型糖尿病的正在进行的临床试验：一项叙述性综述
Curr Diabetes Rev. 2025;21(6):59-74. doi: 10.2174/0115733998294919240506044544.
8
Evaluating the Safety and Efficacy of Sodium-Glucose Co-transporter 2 Inhibitors in Subjects with Prediabetes: A Protocol for a Randomized Controlled Trial.评估钠-葡萄糖协同转运蛋白2抑制剂在糖尿病前期受试者中的安全性和有效性：一项随机对照试验方案
Diabetes Ther. 2024 May;15(5):1231-1244. doi: 10.1007/s13300-024-01560-3. Epub 2024 Mar 18.
9
Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial.恩格列净与2型糖尿病患者肾功能快速下降发生率：来自EMPA-REG OUTCOME试验的探索性分析
Kidney Med. 2023 Dec 18;6(3):100783. doi: 10.1016/j.xkme.2023.100783. eCollection 2024 Mar.
10
Abrupt Decline in Estimated Glomerular Filtration Rate after Initiating Sodium-Glucose Cotransporter 2 Inhibitors Predicts Clinical Outcomes: A Systematic Review and Meta-Analysis.起始钠-葡萄糖共转运蛋白 2 抑制剂后估算肾小球滤过率的急剧下降预测临床结局：系统评价和荟萃分析。
Diabetes Metab J. 2024 Mar;48(2):242-252. doi: 10.4093/dmj.2023.0201. Epub 2024 Jan 26.
1 型糖尿病患者钠-葡萄糖共转运蛋白 2 抑制剂的肾脏血流动力学效应。
Circulation. 2014 Feb 4;129(5):587-97. doi: 10.1161/CIRCULATIONAHA.113.005081. Epub 2013 Dec 13.
4
Combined angiotensin inhibition for the treatment of diabetic nephropathy.联合应用血管紧张素抑制剂治疗糖尿病肾病。
N Engl J Med. 2013 Nov 14;369(20):1892-903. doi: 10.1056/NEJMoa1303154. Epub 2013 Nov 9.
5
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.阿利克仑治疗 2 型糖尿病的心血管和肾脏终点试验。
N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3.
6
Telmisartan, ramipril, or both in patients at high risk for vascular events.替米沙坦、雷米普利或两者联合用于血管事件高危患者。
N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31.
7
Evaluation of renal resistances, with special reference to changes in essential hypertension.肾脏阻力评估，特别提及原发性高血压的变化。
J Clin Invest. 1951 Oct;30(10):1143-55. doi: 10.1172/JCI102534.
8
Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus.短期适度限钠可在血压正常、尿白蛋白正常的Ⅰ型糖尿病患者中诱发相对超滤。
Diabetologia. 2002 Apr;45(4):535-41. doi: 10.1007/s00125-001-0763-8.
9
Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption.实验性糖尿病中的肾小球高滤过：肾小管重吸收的潜在作用。
J Am Soc Nephrol. 1999 Dec;10(12):2569-76. doi: 10.1681/ASN.V10122569.
10
The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies.肾内高血压在糖尿病及其他肾小球疾病发生和进展中的作用。
Am J Med. 1982 Mar;72(3):375-80. doi: 10.1016/0002-9343(82)90490-9.